Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 9/20 | 0.76 |
| ▸ | CA1 | P00915 | 2/20 | 0.69 |
| ▸ | CA2 | P00918 | 2/20 | 0.69 |
| ▸ | CA9 | Q16790 | 2/20 | 0.69 |
| ▸ | ESR1 | P03372 | 4/20 | 0.68 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.68 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.68 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.68 |
| ▸ | SHBG | P04278 | 1/20 | 0.68 |
| ▸ | PGR | P06401 | 1/20 | 0.68 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.68 |
| ▸ | AR | P10275 | 1/20 | 0.68 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.68 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.68 |
| ▸ | SNCA | P37840 | 1/20 | 0.68 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.68 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6369320 | 1.00 | STS (0.76) | STSCA1CA2CA9ESR1 | |
| SCHEMBL5167881 | 0.91 | STS (0.75) | STSCA1CA2CA9ESR1 | |
| SCHEMBL5521870 | 0.91 | ABCC4 (0.76) | STSCA1CA2CA9ESR1 | |
| SCHEMBL2517551 | 0.91 | ABCC4 (0.76) | STSCA1CA2CA9ESR1 | |
| SCHEMBL5164441 | 0.90 | STS (0.74) | STSCA1CA2CA9ESR1 | |
| SCHEMBL5164440 | 0.90 | STS (0.77) | STSCA1CA2CA9ESR1 | |
| SCHEMBL6440061 | 0.90 | KDM4E (0.76) | STSCA1CA2CA9ESR1 | |
| SCHEMBL8214049 | 0.88 | ESR1 (0.66) | STSCA1CA2CA9ESR1 | |
| SCHEMBL6369302 | 0.88 | ESR1 (0.66) | STSCA1CA2CA9ESR1 | |
| SCHEMBL3371578 | 0.88 | ESR1 (0.66) | STSCA1CA2CA9ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9452175-B2 | Pregnancy hormone combination for treatment of autoimmune diseases | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-09-27 | — | — | US | claimed |
| US-20160082017-A1 | ESTRIOL THERAPY FOR MULTIPLE SCLEROSIS AND OTHER AUTOIMMUNE DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2016-03-24 | — | — | US | claimed |
| US-9168262-B2 | Estriol therapy for multiple sclerosis and other autoimmune diseases | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-10-27 | — | — | US | claimed |
| EP-2698167-A2 | Dosage form of an estriol and glatiramer acetate polymer-1 for the treatment of multiple sclerosis | The Regents of The University of California (US) | 2014-02-19 | — | — | EP | claimed |
| US-20130280213-A1 | ESTRIOL THERAPY FOR MULTIPLE SCLEROSIS AND OTHER AUTOIMMUNE DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2013-10-24 | — | — | US | claimed |
| US-20120322779-A9 | Estriol Therapy for Autoimmune and Neurodegenerative Diseases and Disorders | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2012-12-20 | — | — | US | claimed |
| US-20120014915-A9 | Estriol Therapy for Autoimmune and Neurodegenerative Disease and Disorders | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-01-19 | — | — | US | claimed |
| US-20090297477-A1 | Estriol Therapy for Autoimmune and Neurodegenerative Disease and Disorders | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-12-03 | — | — | US | claimed |
| US-20090131385-A1 | Estriol Therapy for Autoimmune and Neurodegenerative Diseases and Disorders | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-05-21 | — | — | US | claimed |
| EP-1929291-A2 | ESTRIOL THERAPY FOR AUTOIMMUNE AND NEURODEGENERATAIVE DISEASES AND DISORDERS | The Regents of the University of California (US) | 2008-06-11 | — | — | EP | claimed |
| WO-2003072109-A1 | USE OF BIOGENIC ESTRIOL SULFAMATE PRODRUGS FOR THE TREATMENT OF AUTOIMMUNE DISEASES | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-09-04 | — | — | WO | claimed |
| JP-2003519658-A | — | — | 2003-06-24 | — | — | JP | claimed |
| CN-1404394-A | Composition comprising a metal oxide and a metal oxide | STERIX LTD (GB) | 2003-03-19 | — | — | CN | claimed |
| US-20020183299-A1 | Estriol therapy for multiple sclerosis and other autoimmune diseases | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2002-12-05 | — | — | US | claimed |
| WO-2002085374-A1 | ESTRIOL THERAPY FOR MULTIPLE SCLEROSIS AND OTHER AUTOIMMUNE DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2002-10-31 | — | — | WO | claimed |
| EP-1248626-A2 | PHARMACEUTICAL COMPOSITIONS CONTAINING STEROIDAL STRUCTURES AND USES THEREOF | Sterix Limited (GB) | 2002-10-16 | — | — | EP | claimed |
| US-20020061868-A1 | Pharmaceutical preparations containing estra-1,3,5(10)-triene derivatives | STERIX LIMITED (GB) | 2002-05-23 | — | — | US | claimed |
| CN-1311683-A | Use of biogenic estrogen sulfamates for hormone replacement therapy | JENAPHARM GMBH (DE) | 2001-09-05 | — | — | CN | claimed |
| WO-2001051055-A2 | PHARMACEUTICAL COMPOSITIONS CONTAINING STEROIDAL STRUCTURES AND USES THEREOF | STERIX LIMITED (GB) | 2001-07-19 | — | — | WO | claimed |
| US-6080735-A | SUITABLE FOR HORMONAL CONTRACEPTION AND CLIMACTERIC HORMONE REPLACEMENT THERAPY (HRT) AS WELL AS FOR TREATMENT OF GYNECOLOGICAL AND ANDROLOGICAL DISEASES | JENAPHARM GMBH & CO. KG (DE) | 2000-06-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020061868-A1 | Pharmaceutical preparations containing estra-1,3,5(10)-triene derivatives | ESRRA, ESR2, CYP19A1 | STS 124/4885CA1 3531/4885CA2 4144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.